Pitt Innovators Deliver Robust Year of Impact in Fiscal 2026
Fiscal Year 2026 marked a year of remarkable progress across the University of Pittsburgh’s... Read more
REGENTYSâ„¢ is a development stage, regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders. Their first product, ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.